Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Convalescent ...

Convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover, according to a national clinical trial ...

Convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover, according to a national clinical trial ...

WASHINGTON - The final results of a clinical trial show convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19, the National Institutes of Health ...

UVA Health is launching a clinical trial to test the effectiveness of using plasma from patients that have recovered from COVID-19 as a potential treatment for inpatients with the disease. Inpatients ...

The highly infectious severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus, the causal agent of coronavirus disease 2019 (COVID-19) pandemic, has infected over 517 million individuals ...

CHICAGO (WLS) -- As the COVID-19 pandemic spreads, hospitals around the world have begun testing convalescent plasma as a potential treatment. The University of Chicago Medicine is one facility who is ...

The results of a nationwide, multicenter clinical trial led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health provide solid evidence for the use of plasma from ...

Two ongoing trials may provide additional clarity regarding the use of convalescent plasma in patients with Covid-19. The COVIC-19 trial (Early High-Titre Convalescent Plasma in Clinically Vulnerable ...

Some longtime advocates of the therapy say they’re pessimistic about its future. This is a Kaiser Health News story. Six months after it was controversially hailed by Trump administration officials as ...

Convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover, according to a national clinical trial.